TABLE 1.

Patients’ characteristics and peritoneal pDC content

Subject ID	Age (years)	Sex	Primary site	Histologic type	Collection timea	Collection method	% pDC
GI0791	62	F	Colon	Adenocarcinoma	Post-chemotherapy	OR	1.41
GI0794	66	M	Appendix	Adenocarcinoma	Pre-chemotherapy	OR	0.79
GI0812	51	F	Pancreas	Adenocarcinoma	Pre-chemotherapy	US	3.94
GI0827	68	F	Appendix	Adenocarcinoma	On chemotherapy	OR	0.17
GI0828	69	M	Pancreas	Mucinous adenocarcinoma	Pre-chemotherapy	OR	4.73
GI0830	64	F	Pancreas	Adenocarcinoma	On chemotherapy	US	0.62
GI0863	62	M	Appendix	Mucinous adenocarcinoma	Pre-chemotherapy	US	1.32
GI0866	67	F	Appendix	Signet ring cell carcinoma	Post-chemotherapy	OR	0.41
GI0896	57	F	Appendix	Goblet cell carcinoma	Post-chemotherapy	OR	0.39
GI0949	56	M	Colon	Adenocarcinoma	Post-chemotherapy	OR	0.53
GI0970	23	M	Rectum	Adenocarcinoma	Post-chemotherapy	OR	0.87
GI0955	40	F	Small bowel	Adenocarcinoma	Post-chemotherapy	OR	2.60
GI1005	44	F	Colon	Adenocarcinoma	On pembrolizumab	OR	0.01
GI1034	56	F	Appendix	Adenocarcinoma	On chemotherapy	US	0.58
GI1050	60	F	Pancreas	Adenocarcinoma	Pre-chemotherapy	OR	1.17
GI1095	54	M	Rectum	Adenocarcinoma	On chemotherapy	OR	0.06
GI1107	47	F	Colon	Adenocarcinoma	Post-chemotherapy	OR	0.06

OR intraoperative ascites drainage or peritoneal lavage, US ultrasound-guided paracentesis

^a“Postchemotherapy” (patients received their last chemotherapy dose within 4 weeks after fluid collection); “Pre-chemotherapy” (patients did not receive chemotherapy or other therapy for at least 6 months); “On chemotherapy” (patients received active chemotherapy within 4 weeks after fluid collection; On pembrolizumab (patient received pembrolizumab after fluid collection)